ADRM1 is a receptor for ubiquitin, a small regulatory protein that tags other proteins for degradation. By binding to ubiquitinated proteins, ADRM1 facilitates their recognition and processing by the proteasome. This process is vital for the regulation of protein turnover, which in turn affects numerous cellular functions such as cell cycle progression, apoptosis, and DNA repair .
Recent studies have highlighted the significance of ADRM1 in cancer development and progression. Elevated levels of ADRM1 have been observed in various types of cancers, including bladder cancer. In bladder cancer, high ADRM1 expression is associated with poor prognosis and increased tumor aggressiveness. ADRM1’s role in cancer is linked to its involvement in regulating immune-related pathways and its interaction with immune checkpoints such as CD274 (PD-L1), PDCD1 (PD-1), and PDCD1LG2 (PD-L2) .
Mouse anti-human ADRM1 antibodies are monoclonal antibodies developed to specifically target the human ADRM1 protein. These antibodies are used in research to study the expression and function of ADRM1 in various biological contexts. They are particularly valuable in immunohistochemistry (IHC) and other immunoassays to detect ADRM1 in tissue samples and cell lines .
The use of mouse anti-human ADRM1 antibodies has facilitated numerous studies aimed at understanding the role of ADRM1 in health and disease. For instance, these antibodies have been employed to investigate the expression patterns of ADRM1 in cancer tissues, providing insights into its potential as a biomarker for cancer diagnosis and prognosis. Additionally, research utilizing these antibodies has contributed to the development of targeted therapies aimed at modulating ADRM1 activity to improve cancer treatment outcomes .